Arsenite induces HIF-1α and VEGF through PI3K, Akt and reactive oxygen species in DU145 human prostate carcinoma cells

Molecular and Cellular Biochemistry

Volumn 255, Issue 1-2, 2004, Pages 33-45

  Gao, Ning ^a   Shen, Liqin ^b   Zhang, Zhuo ^c   Leonard, Stephen S ^c   He, Hengjun ^c   Zhang, Xue Guang ^b   Shi, Xianglin ^c   Jiang, Bing Hua ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b SUZHOU UNIVERSITY   (China)

^c NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH   (United States)

Author keywords

Akt; Hypoxia inducible factor 1 (HIF 1); MAP kinase kinase (MEK); Mitogen activated protein kinase (MAPK); Phosphatidylinositol 3 kinase (PI3K); Reactive oxygen species (ROS); Vascular endothelial growth factor (VEGF)

Indexed keywords

ARSENIC TRIOXIDE; HELIX LOOP HELIX PROTEIN; HYDROGEN PEROXIDE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN SUBUNIT; REACTIVE OXYGEN METABOLITE; VASCULOTROPIN;

ANGIOGENESIS; CARCINOMA CELL; CHEMICAL CARCINOGENESIS; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MALE; PROSTATE CARCINOMA; PROTEIN EXPRESSION; PROTEIN INDUCTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANDROSTADIENES; ARSENITES; CELL LINE, TUMOR; CHROMONES; DNA-BINDING PROTEINS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MORPHOLINES; NUCLEAR PROTEINS; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; TERATOGENS; TRANSCRIPTION FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 0742289407     PISSN: 03008177     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:MCBI.0000007259.65742.16     Document Type: Review

References (71)

1. Kitchin KT: Recent advances in arsenic carcinogenesis: Modes of action, animal model systems, and methylated arsenic metabolites. Toxicol Appl Pharmacol 172: 249-261, 2001
2. Faroon OM, Williams M, O'Connor R: A review of the carcinogenicity of chemicals most frequently found at National Priorities List sites. Toxicol Ind Health 10: 203-230, 1994
3. Rojas E, Herrera LA, Poirier LA, Ostrosky-Wegman P: Are metal dietary carcinogens? Mutat Res 443: 157-181, 1999
4. Chen CJ, Wang CJ: Ecological correlation between arsenic level in well water and age-adjusted mortality from malignant neoplasms. Cancer Res 50: 5470-5474, 1990
5. Chiou H-Y, Hsueh YM, Liaw KF, Horng SF, Chiang MH, Pu YS, Lin JS, Huang CH, Chen CJ: Incidence of internal cancers and ingested inorganic arsenic: A seven year follow up study in Taiwan. Cancer Res 55: 1296-1330, 1995
6. Chen CJ, Chen CW, Wu M-M, Kuo T-L: Cancer potential in liver, lung, bladder and kidney due to ingested inorganic in drinking water. Br J Cancer 66: 888-892, 1992
7. Li JH, Rossman TG: Comutagenesis of sodium arsenite with ultraviolet radiation in Chinese hamster V79 cells. Biol Metals 4: 197-200, 1991
8. Lee-Chen SF, Yu CT, Jan KY: Effect of arsenite on the DNA repair of UV-irradiated Chinese hamster ovary cells. Mutagenesis 7: 51-55, 1992
9. Salazar AM, Ostrosky-Wegman P, Menendez D, Miranda E, Garcia-Carranca A, Rojas E: Induction of p53 protein expression by sodium arsenite. Mutat Res 381: 259-265, 1997
10. Chen F, Zhang Z, Bower J. Lu Y, Leonard SS, Ding M, Castranova V, Piwnica-Worms H, Shi X: Arsenite-induced Cdc25C degradation is through the KEN-box and ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 99: 1990-1995, 2002
11. Miller WH Jr, Schipper HM, Lee JS, Singer J, Waxman S: Mechanisms of activation of arsenic trioxide. Cancer Res 62: 3893-3903, 2002
12. Kim JY, Choi JA, Kim TH, Yoo YD, Kim JI, Lee YJ, Yoo SY, Cho CK, Lee YS, Lee SJ: Involvement of p38 mitogen-activated protein kinase in the cell growth inhibition by sodium arsenite. J Cell Physiol 190: 29-37, 2002
13. Chen F, Lu Y, Zhang Z, Vallyathan Y, Ding M, Castranova V, Shi X: Opposite effect of NF-κB and c-Jun N-terminal kinase on p53-independent GADD45 induction by arsenite. J Biol Chem 276: 11414-11419, 2001
14. Cavigelli M, Li WW, Lin A, Su B, Yoshioka K, Karin M: The tumor promoter arsenite stimulates AP-1 activity by inhibiting a JNK phosphatase. EMBO J 15: 6269-6279, 1996
15. Hayes RB: The carcinogenicity of metals in humans. Cancer Causes Control 8: 371-385, 1997
16. Jiang BH, Rue E, Wang GL, Roe R, Semenza GL: Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J Biol Chem 271: 17771-17778, 1996
17. 2 tension. Proc Natl Acad Sci USA 92: 5510-5514, 1995
18. 2 tension. Am J Physiol 271: C1172-C1180, 1996
19. Hoffman EC, Reyes H, Chu FF, Sander F, Conley LH, Brooks BA, Hankinson O: Cloning of a factor required for activity of the Ah (dioxin) receptor. Science 252: 954-958, 1991
20. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL: Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16: 4604-4613, 1996
21. Lee PJ, Jiang BH, Chin BY, Lyer NV, Alam J, Semenza GL, Choi AM: Hypoxia-inducible factor-1 mediates transcriptional activation of the heme oxygenase-1 gene in response to hypoxia. J Biol Chem 272: 5375-5381, 1997
22. Semenza GL, Jiang BH, Leung SW, Passantino R, Concordet JP, Maire P, Giallongo A: Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem 271: 32529-32537, 1996
23. Semenza GL, Agani F, Booth G, Forsythe J, Iyer N, Jiang BH, Leung S, Roe R, Wiener C, Yu A: Structural and functional analysis of by poxia-inducible factor 1. Kidney Int 51: 553-555, 1997
24. Jiang BH, Agani F, Passaniti A, Semenza GL: V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: Involvement of HIF-1 in tumor progression. Cancer Res 57: 5328-5335, 1997
25. Maxwell PH, Dachs GU, Gleadle JM, Nicholls LG, Harris AL, Stratford IJ, Hankinson O, Pugh CW, Ratcliffe PJ: Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 94: 8104-8109, 1997
26. Mazure NM, Chen EY, Laderoute KR, Giaccia AJ: Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood 90: 3322-3331, 1997
27. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW: Overexpression of hypoxia-inducible factor 1 alpha in common human cancers and their metastases. Cancer Res 59: 5830-5835, 1999
28. Jiang BH, Jiang G, Zheng JZ, Lu Z, Hunter T, Vogt PK: Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Diff 12: 363-369, 2001
29. Minet E, Arnould T, Michel G, Roland I, Mottet D, Raes M, Remacle J, Michiels C: ERK activation upon hypoxia: Involvement in HIF-1 activation. FEBS Lett 468: 53-58, 2000
30. Richard DE, Berra E, Gothie E, Roux D, Pouyssegur J: p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor I alpha (HIF-1 alpha) and enhance the transcriptional activity of HIF-1. J Biol Chem 274: 32631-32637, 1999
31. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, Simons JW, Semenza GL: Modulation of hypoxia-inducible factor 1 alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: Implications for tumor angiogenesis and therapeutics. Cancer Res 60: 1541-1545, 2000
32. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ: The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399: 271-275, 1999
33. Cockman ME, Masson N, Mole DR, Jaakkola P, Chang GW, Clifford SC, Maher ER, Pugh CW, Ratcliffe PJ, Maxwell PH: Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 275: 25733-25741, 2000
34. Kamura T, Sato S, Iwai K, Czyzyk-Krzeska M, Conaway RC, Conaway JW: Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci USA 97: 10430-10435, 2000
35. Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE, Pavietich N, Chau V, Kaelin WG: Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2: 423-427, 2000
36. Tanimoto K, Makino Y, Pereira T, Poellinger L: Mechanism of regulation of the hypoxia- inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J 19: 4298-4309, 2000
37. Bruick RK, McKnight SL: A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294: 1337-1340, 2001
38. 2-regulated prolyl hydroxylation. Science 292: 468-472, 2001
39. Masson N, Wiliam C, Maxwell PH, Pugh CW, Ratcliffe PJ: Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. EMBO J 20: 5197-5206, 2001
40. Liu Y, Cox SR, Morita T, Kourembanas S: Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5′ enhancer. Circ Res 77: 638-643, 1995
41. Ferrara N, Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev 18: 4-25, 1997
42. Millauer B, Longhi MP, Plate KH, Shawver LK, Risau W, Ullrich A, Strawn LM: Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res 56: 1615-1620, 1996
43. Plate KH, Breier G, Weich HA, Risau W: Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359: 845-848, 1992
44. Plate KH, Breier G, Millauer B, Ullrich A, Risau W: Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res 53: 5822-5827, 1993
45. Strawn LM, McMahon G, App H, Schreck R, Kuchler WR, Longhi MP, Hui TH, Tang C, Levitzki A, Gazit A, Chen I, Keri G, Orfi L, Risau W, Flamme I, Ullrich A, Hirth KP, Shawver LK: Flk-1 as a target for tumor growth inhibition. Cancer Res 56: 3540-3545, 1996
46. Liu SX, Athar M, Lippai I, Waldren C, Hei TK: Induction of oxyradicals by arsenic: Implication for mechanism of genotoxicity. Proc Natl Acad Sci USA 98: 1643-1648, 2001
47. Ding M, Li J-J, Leonard SS, Ye J, Shi X, Colburn NH, Castranova V, Vallyathan V: Vanadate-induced activation of activator protein-1: Role of reactive oxygen species. Carcinogenesis 20: 663-668, 1999
48. Ye J, Ding M, Leonard SS, Robinson VA, Michecchia L, Zhang X, Castranova V, Vallyathan V, Shi X: Vanadate induces apoptosis in epidermal JB6 P+ cells via hydrogen peroxide-mediated reactions. Mol Cell Biochem 202: 9-17, 1999
49. Wang S, Leonard SS, Ye J, Ding M, Shi X: The role of hydroxyl radical as a messenger in Cr(VI)-induced p53 activation. Am J Physiol Cell Physiol 279: C868-C875, 2000
50. Ye J, Wang S, Leonard SS, Sun Y, Butterworth L, Antonini J, Ding M, Rojanasakul Y, Vallyathan V, Castranova V, Shi X: Role of reactive oxygen species and p53 in chromium(VI)-induced apoptosis. J Biol Chem 274: 34974-34980, 1999
51. Wang S, Shi X: Mechanisms of Cr(VI)-induced p53 activation: The role of phosphorylation, mdm2 and ERK. Carcinogenesis 22: 757-762, 2001
52. Shi X, Mao Y, Knapton AD, Ding M, Rojanasakul Y, Gannett PM, Dalal NS, Liu K: Reaction of Cr(VI) with ascorbate and hydrogen peroxide generates hydroxyl radicals and causes DNA damage: Role of Cr(IV)-mediated Fenton-like reaction. Carcinogenesis 15: 2475-2478, 1994
53. Shi X, Dalal NS: Chromium (V) and hydroxyl radical formation during the glutathione reductase-catalyzed reduction of chromium (VI). Biochem Biophys Res Commun 163: 627-634, 1989
54. Shi X, Dalal NS: On the hydroxyl radical formation in the reaction between hydrogen peroxide and biologically generated chromium (V) species. Arch Biochem Biophys 277: 342-350, 1990
55. Salceda S, Caro J: Hypoxia-inducible factor 1alpha (HIF-1 alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem 272: 22642-22647, 1997
56. Sandau KB, Fandrey J, Brune B: Accumulation of HIF-1 alpha under the influence of nitric oxide. Blood 97: 1009-1015, 2001
57. Feldser D, Agani F, Lyer V, Ferrcira G, Semenza GL: Reciprocal positive regulation of hypoxia-inducible factor-1 alpha and insulin-like growth factor 2. Cancer Res 59: 3915-3918, 1999
58. Goldwaser I, Gefel D, Gershonov E, Fridkin M, Shechter Y: Insulin-like effects of vanadium: Basic and clinical implications. J Inorg Biochem 80: 21-25, 2000
59. Barbagallo M, Dominguez LJ, Resnick LM: Insulin-mimetic action of vanadate: Role of intracellular magnesium. Hypertersion. 38: 701-704, 2001
60. Minet E, Michel G, Remade J, Michiels C: Role of HIF-1 as a transcription factor involved in embryonic development, cancer progression and apoptosis (review). Int J Mol Med 5: 253-259, 2000
61. Zelzer E, Levy Y, Kahana C, Shilo BZ, Rubinstein M, Cohen B: Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1α/ARNT. EMBO J. 17: 5085-5094, 1998
62. Gong P, Hu B, Steward D, Ellerbe M, Figueroa YG, Blank V, Beckman BS, Alam J: Cobalt induces heme oxygenase-1 expression by a hypoxia-inducible factor-independent mechanism in Chinese hamster ovary cells: Regulation by Nrf2 and MafG transcription factors. J Biol Chem 276:27018-27025, 2001
63. Kotch LE, Iyer NV, Laughner E, Semenza GL: Defective vascularization of HIF-1alpha-null embryos is not associated with VEGF deficiency but with mesenchymal cell death. Dev Biol 209: 254-267, 1999
64. Benjamin LE, Keshet E: Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: Induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc Natl Acad Sci USA 94: 8761-8766, 1997
65. Borgstrom P, Hillan KJ, Sriramarao P, Ferrara N: Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: Novel concepts of angiostatic therapy from intravital videonvicroscopy. Cancer Res 56: 4032-4039, 1996
66. Cheng S-Y, Huang H-JS, Nagane M, Ji X-D, Wang D, Shih CC-Y, Arap W, Huang C-M, Cavenee WK: Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc Natl Acad Sci USA 93: 8502-8507, 1996
67. Grunstein J, Roberts WG, Mathieu-Costello O, Hanahan D, Johnson RS: Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. Cancer Res 59: 1592-1598, 1999
68. Richard DE, Berra E, Pouyssegur J: Nonhypoxic pathway mediates the induction of hypoxia-inducible factor 1alpha in vascular smooth muscle cells. J Biol Chem 275: 26765-26771, 2000
69. Fandrey J, Frede S, Jelkmann W: Role of hydrogen peroxide in hypoxia-induced erythropoietin production. Biochem J 303: 507-510, 1994
70. Chandel NS, Maltepe E, Goldwasser E, Mathieu CE, Simon MC, Schumacker PT: Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Proc Natl Acad Sci USA 95: 11715-11720, 1998
71. 2 sensing. J Biol Chem 275: 25130-25138, 2000